Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics (AQST)
NASDAQ:AQST
RESEARCH TOOLSreports
Holding AQST?
Track your performance easily
Earnings Data
Report Date
Mar 11, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.13Last Year’s EPS
-$0.12Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 04, 2024
|% Change Since: -29.13%
|Next Earnings Date:Mar 11, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in product development and market access, with positive clinical study outcomes and expanded commercial capabilities. However, financial challenges were evident with increased net losses and higher expenses.Company Guidance
During the AQST Q3 2024 earnings call, Aquestive Therapeutics provided robust guidance on several fronts. They reported a 4% increase in total revenues to $13.5 million for the quarter, driven by increased license and royalty revenues, although manufacture and supply revenue decreased slightly. The company highlighted the significant progress with their Anaphylm product, noting that the median time to full symptom resolution during the OASIS study was reduced to 12 minutes with Anaphylm, compared to 74 minutes without it. Aquestive also emphasized their commercial progress with Libervant, now covered by Medicaid in all 50 states, and reported a 22% increase in total revenues for the first nine months of 2024 compared to the same period last year. Their financial guidance for 2024 remains unchanged, with expected total revenues of $57 million to $60 million and a non-GAAP adjusted EBITDA loss of $20 million to $23 million. Additionally, Aquestive plans to file for Anaphylm's NDA in Q1 2025 and anticipates a potential launch in Q1 2026, if approved.Major Product Developments
Announced a new product candidate, AQST-108, for alopecia areata. Expanded Libervant launch in the 2- to 5-year-old demographic. Completed final adult study for Anaphylm and submitted pre-NDA briefing book to the FDA.
Anaphylm Clinical Study Success
OASIS study confirmed Anaphylm absorption profile remains unchanged with or without an allergen, demonstrating significant symptom resolution improvements.
Commercial Expansion and Market Access
Libervant achieved Medicaid coverage in all 50 states and agreements with two of the top three PBMs.
Revenue Growth
Total revenues increased by 4% to $13.5 million in Q3 2024, driven by license and royalty revenue.
Positive CMC Feedback from FDA
Received supportive responses from the FDA on the chemistry, manufacturing, and controls pre-NDA questions for Anaphylm.
---
AQST Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AQST Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 04, 2024 | $5.15 | $4.76 | -7.57% |
| Aug 06, 2024 | $3.40 | $3.43 | +0.88% |
| May 07, 2024 | $3.38 | $3.08 | -8.88% |
| Mar 05, 2024 | $4.19 | $5.03 | +20.05% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Aquestive Therapeutics (AQST) report earnings?
Aquestive Therapeutics (AQST) is schdueled to report earning on Mar 11, 2025, TBA Not Confirmed.
What is Aquestive Therapeutics (AQST) earnings time?
Aquestive Therapeutics (AQST) earnings time is at Mar 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AQST EPS forecast?
AQST EPS forecast for the fiscal quarter 2024 (Q4) is -$0.13.
---